Related Articles
Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab
EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
Nimotuzumab, an EGFR‑targeted antibody, promotes radiosensitivity of recurrent esophageal squamous cell carcinoma
Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma (Review)
Efficacy of cetuximab‑based chemotherapy in metastatic colorectal cancer according to RAS and BRAF mutation subgroups: A meta‑analysis